The global cancer diagnostics market is projected to grow from USD 29.86 billion in 2026 to USD 44.92 billion by 2031, at a CAGR of 7.0% during the forecast period. The market was valued at USD 27.62 billion in 2025.

The rising global burden of cancer, coupled with increasing awareness of the importance of early detection and timely diagnosis, is a major factor driving demand for cancer diagnostics. Growing incidences of breast, lung, colorectal, prostate, and other cancers are accelerating the adoption of advanced diagnostic technologies such as molecular diagnostics, liquid biopsy, next-generation sequencing (NGS), immunohistochemistry (IHC), and companion diagnostics.

The expanding aging population, increasing healthcare expenditure, and government-led cancer screening initiatives are further supporting market growth. In addition, continuous advancements in precision oncology, biomarker-based testing, digital pathology, and AI-enabled diagnostic solutions are improving diagnostic accuracy, reducing turnaround times, and enabling personalized treatment decisions. As healthcare providers increasingly emphasize early cancer detection and targeted therapies, demand for cancer diagnostic solutions across hospitals, clinical laboratories, and specialized cancer centers is expected to remain strong throughout the forecast period.

Spotlights on the Industry’s Leading Cancer Diagnostics Companies

The cancer diagnostics market is evolving rapidly, driven by advances in molecular diagnostics, liquid biopsy, next-generation sequencing, biomarker testing, digital pathology, and artificial intelligence. In this dynamic environment, the following companies stand out for their diagnostic technologies, research capabilities, product portfolios, and contributions to precision oncology and cancer detection worldwide.

1. Roche Diagnostics

Roche Diagnostics is a major participant in the cancer diagnostics market, offering a broad portfolio of molecular diagnostics, tissue-based testing, immunohistochemistry, companion diagnostics, and biomarker assessment solutions. Its diagnostic technologies support cancer detection, disease characterization, and treatment selection. The company’s integration of pathology and molecular testing capabilities supports the growing adoption of precision oncology.

2. Danaher Corporation

Danaher Corporation participates in cancer diagnostics through companies including Cepheid, Leica Biosystems, and Beckman Coulter. Its portfolio spans molecular diagnostics, tissue diagnostics, pathology, laboratory automation, and clinical diagnostic technologies. These capabilities support cancer screening, biomarker analysis, tissue characterization, and efficient laboratory workflows across healthcare settings.

3. Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. provides technologies supporting molecular diagnostics, next-generation sequencing, genomic analysis, and research applications in oncology. Its portfolio enables laboratories and research institutions to analyze genetic and molecular characteristics associated with cancer. Continued advances in sequencing and precision medicine are expanding opportunities for genomic-based cancer diagnostics.

4. Abbott Laboratories

Abbott Laboratories offers diagnostic technologies supporting cancer screening, biomarker testing, molecular analysis, and laboratory-based diagnosis. Its diagnostic portfolio serves hospitals, clinical laboratories, and healthcare providers worldwide. The company’s focus on diagnostic innovation supports the growing demand for accurate and accessible cancer testing.

5. Siemens Healthineers AG

Siemens Healthineers AG contributes to cancer diagnostics through imaging, laboratory diagnostics, and advanced healthcare technologies. Its solutions support cancer detection and diagnostic workflows across hospitals and healthcare systems. Integration of imaging, laboratory data, and digital technologies is increasingly important for improving diagnostic pathways and supporting personalized cancer care.

6. Agilent Technologies, Inc.

Agilent Technologies, Inc. provides technologies supporting cancer diagnostics, particularly in pathology, molecular analysis, biomarker testing, and tissue-based diagnostics. Its solutions enable laboratories to investigate molecular and cellular characteristics associated with cancer. The company’s focus on precision testing supports the expanding role of biomarker-driven diagnosis in oncology.

7. QIAGEN N.V.

QIAGEN N.V. is a key provider of molecular diagnostic technologies used for cancer-related testing and biomarker analysis. Its portfolio includes sample preparation, nucleic acid extraction, molecular testing, and companion diagnostic solutions. These technologies support the increasing adoption of molecular approaches for cancer detection and treatment selection.

8. Illumina, Inc.

Illumina, Inc. plays an important role in genomic cancer diagnostics through its next-generation sequencing technologies. Its platforms enable comprehensive analysis of genetic alterations and biomarkers associated with cancer. Increasing use of genomic profiling in precision oncology continues to create demand for advanced sequencing-based diagnostic solutions.

9. Hologic, Inc.

Hologic, Inc. has a strong presence in women’s health diagnostics and cancer screening. Its technologies support cervical cancer screening and other diagnostic applications, helping healthcare providers identify disease at earlier stages. The company’s focus on screening and molecular diagnostic technologies contributes to the expanding cancer diagnostics landscape.

10. Becton, Dickinson and Company (BD)

Becton, Dickinson and Company (BD) provides diagnostic and laboratory technologies that support cancer-related testing, cellular analysis, and laboratory workflows. Its solutions contribute to the detection and characterization of cellular abnormalities and support efficient diagnostic processes. Automation and standardized laboratory workflows remain important areas of focus.

11. Exact Sciences Corporation

Exact Sciences Corporation specializes in cancer screening and diagnostic solutions, with a particular focus on early cancer detection. Its technologies support screening and molecular testing approaches designed to identify cancer-related biomarkers. The company’s emphasis on noninvasive and molecular-based testing aligns with the growing demand for earlier cancer detection.

12. Guardant Health, Inc.

Guardant Health, Inc. focuses on precision oncology and blood-based cancer diagnostics. Its liquid biopsy technologies enable analysis of circulating tumor DNA and other biomarkers from blood samples. These approaches support cancer detection, treatment selection, and disease monitoring while contributing to the growing adoption of minimally invasive diagnostic technologies.

13. Foundation Medicine, Inc. (Roche)

Foundation Medicine, Inc., a Roche company, specializes in comprehensive genomic profiling for cancer. Its diagnostic solutions analyze tumor genomic alterations to support personalized treatment decisions. The company’s focus on precision oncology and biomarker identification contributes to the increasing use of genomic information in cancer care.

14. Sysmex Corporation

Sysmex Corporation provides diagnostic technologies supporting hematology, laboratory testing, and cancer-related diagnostic applications. Its expertise in automated laboratory systems and advanced analytical technologies supports efficient clinical workflows. The company continues to contribute to the broader development of technology-enabled diagnostic testing.

15. bioMérieux SA

bioMérieux SA provides in vitro diagnostic technologies supporting clinical laboratories and disease detection. Its molecular and microbiology capabilities contribute to cancer-related diagnostic workflows and patient management. The company’s focus on diagnostic innovation and laboratory automation supports the increasing demand for advanced clinical testing.

16. Myriad Genetics, Inc.

Myriad Genetics, Inc. specializes in genetic testing and precision medicine, with significant applications in oncology. Its testing solutions help identify genetic and hereditary factors associated with cancer risk and support personalized clinical decision-making. Growing awareness of hereditary cancer risk is contributing to demand for genetic testing.

17. NeoGenomics Laboratories, Inc.

NeoGenomics Laboratories, Inc. provides specialized cancer testing services covering pathology, molecular diagnostics, cytogenetics, and biomarker analysis. Its comprehensive testing capabilities support oncologists and healthcare providers in cancer diagnosis and treatment planning. The company’s specialized laboratory model addresses the growing demand for advanced oncology diagnostics.

18. Natera, Inc.

Natera, Inc. develops molecular diagnostic technologies with applications in oncology, including blood-based testing and molecular monitoring. Its technologies support the analysis of tumor-related genetic information and help advance personalized approaches to cancer management. The increasing use of minimally invasive molecular testing is supporting opportunities in this segment.

19. Tempus AI, Inc.

Tempus AI, Inc. combines artificial intelligence, genomic data, and clinical information to support precision oncology. Its technologies are designed to analyze large volumes of clinical and molecular data, helping healthcare providers identify relevant biomarkers and inform treatment decisions. The integration of AI and genomic data is becoming an important area of innovation in cancer diagnostics.

20. GRAIL, Inc.

GRAIL, Inc. focuses on early cancer detection through blood-based testing technologies. Its approach involves analyzing molecular signals associated with multiple cancers from blood samples. The company’s work reflects the growing interest in multi-cancer early detection and the potential role of liquid biopsy technologies in expanding cancer screening.

Conclusion: 

The cancer diagnostics market is undergoing significant transformation as healthcare systems place greater emphasis on early detection, precision oncology, biomarker testing, and personalized treatment. Molecular diagnostics, liquid biopsy, next-generation sequencing, immunohistochemistry, companion diagnostics, digital pathology, and AI-enabled solutions are expected to remain important areas of technological development.

The companies highlighted above represent key participants across different segments of the cancer diagnostics ecosystem, including genomic testing, pathology, molecular diagnostics, cancer screening, liquid biopsy, laboratory diagnostics, and AI-enabled precision oncology.